Nothing Special   »   [go: up one dir, main page]

HK1174264A1 - 使用 -鳥氨酸苯乙酸鹽治療門靜脈高壓和恢復肝功能 - Google Patents

使用 -鳥氨酸苯乙酸鹽治療門靜脈高壓和恢復肝功能

Info

Publication number
HK1174264A1
HK1174264A1 HK13101381.0A HK13101381A HK1174264A1 HK 1174264 A1 HK1174264 A1 HK 1174264A1 HK 13101381 A HK13101381 A HK 13101381A HK 1174264 A1 HK1174264 A1 HK 1174264A1
Authority
HK
Hong Kong
Prior art keywords
restoration
treatment
liver function
portal hypertension
ornithine phenylacetate
Prior art date
Application number
HK13101381.0A
Other languages
English (en)
Inventor
Rajiv Jalan
Keith Anderson
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of HK1174264A1 publication Critical patent/HK1174264A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK13101381.0A 2009-06-08 2013-01-31 使用 -鳥氨酸苯乙酸鹽治療門靜脈高壓和恢復肝功能 HK1174264A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18515809P 2009-06-08 2009-06-08
US24074809P 2009-09-09 2009-09-09
US29637710P 2010-01-19 2010-01-19
PCT/US2010/037838 WO2010144498A2 (en) 2009-06-08 2010-06-08 Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate

Publications (1)

Publication Number Publication Date
HK1174264A1 true HK1174264A1 (zh) 2013-06-07

Family

ID=43309444

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13101381.0A HK1174264A1 (zh) 2009-06-08 2013-01-31 使用 -鳥氨酸苯乙酸鹽治療門靜脈高壓和恢復肝功能
HK15104252.8A HK1203419A1 (zh) 2009-06-08 2015-05-05 使用 -鳥氨酸乙酸鹽恢復肝功能

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15104252.8A HK1203419A1 (zh) 2009-06-08 2015-05-05 使用 -鳥氨酸乙酸鹽恢復肝功能

Country Status (19)

Country Link
US (2) US20120157526A1 (zh)
EP (3) EP2440200B8 (zh)
JP (3) JP5749255B2 (zh)
KR (2) KR20170026672A (zh)
CN (2) CN102625699B (zh)
AU (1) AU2010258888B2 (zh)
BR (1) BRPI1012956A8 (zh)
CA (2) CA2997484C (zh)
DK (2) DK2440200T3 (zh)
EA (2) EA025735B1 (zh)
ES (2) ES2728948T3 (zh)
HK (2) HK1174264A1 (zh)
IL (2) IL216811A (zh)
MX (2) MX2011013129A (zh)
NZ (2) NZ615091A (zh)
PL (1) PL2440200T3 (zh)
SG (1) SG176675A1 (zh)
WO (1) WO2010144498A2 (zh)
ZA (1) ZA201108988B (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA011716B1 (ru) 2004-11-26 2009-04-28 Ю Си Эл БИЗНЕС Пи Эл Си Композиция, содержащая орнитин и фенилацетат или фенилбутират, для лечения печеночной энцефалопатии
SG174982A1 (en) 2009-04-03 2011-11-28 Ocera Therapeutics Inc L-ornithine phenyl acetate and methods of making thereof
SG176675A1 (en) 2009-06-08 2012-01-30 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
CA2813563C (en) 2010-10-06 2019-02-26 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate
CN102993037B (zh) * 2012-11-20 2015-03-04 南京工业大学 一种l-鸟氨酸苯乙酸盐的制备方法
AU2015212606B2 (en) 2014-01-29 2019-11-21 Umecrine Cognition Ab Steroid compound for use in the treatment of hepatic encephalopathy
FI3978074T3 (fi) 2014-10-24 2024-05-20 Mallinckrodt Pharmaceuticals Ireland Ltd Terlipressiini tyypin 1 hepatorenaalisen syndrooman hoitamiseksi
EA201790913A1 (ru) * 2014-11-24 2017-11-30 Юсл Бизнес Плс Лечение заболеваний, связанных с активацией звездчатых клеток печени, с применением видов терапии, снижающих уровень аммиака
AR103384A1 (es) 2015-01-12 2017-05-03 Umecrine Cognition Ab 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA
RU2755904C2 (ru) * 2015-04-20 2021-09-22 Осера Терапьютикс, Инк. Составы l-орнитин фенилацетата
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療
JP6990170B2 (ja) * 2015-08-18 2022-01-12 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防
WO2017053613A1 (en) * 2015-09-25 2017-03-30 Ocera Therapeutics, Inc. Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
AU2016353350B2 (en) * 2015-11-13 2021-09-23 Ocera Therapeutics, Inc. Formulation of L-ornithine phenylacetate
US11219611B2 (en) * 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
CN106109429A (zh) * 2016-07-26 2016-11-16 北京百奥药业有限责任公司 一种苯丁酸钠片剂及其制备方法
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US11160826B1 (en) 2017-03-03 2021-11-02 United States Government As Represented By The Department Of Veterans Affairs Cholesterol lowering drugs for the treatment of hepatic encephalopathy
IL270413B (en) 2017-05-11 2022-08-01 Ocera Therapeutics Inc Processes for the preparation of l-ornithine phenylacetate
TWI775921B (zh) 2017-08-14 2022-09-01 美商胺細拉健康公司 用於治療和高血氨症或肌肉耗損中之一者或兩者相關之肝疾病及失調之組合物及方法
WO2019173148A1 (en) * 2018-03-05 2019-09-12 The United States Government As Represented By The United States Department Of Veterans Affairs Cholesterol lowering drugs for the treatment of hepatic encephalopathy
AR115585A1 (es) 2018-06-20 2021-02-03 Axcella Health Inc Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo
KR102237526B1 (ko) * 2019-11-07 2021-04-07 한국식품연구원 오르니틴 생성능이 우수한 락토바실러스 브레비스 wikim47를 이용한 마늘 발효 조성물

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB965637A (en) 1962-04-23 1964-08-06 Tanabe Seiyaku Co L-ornithine l-aspartate
NL302572A (zh) 1962-12-27
GB1067742A (en) 1963-09-16 1967-05-03 Kyowa Hakko Kogyo Kk Process for the preparation of l-ornithine l-aspartate
ZA716628B (en) 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
FR2113774A1 (en) 1970-11-13 1972-06-30 Roques Ets Prepn of l-ornithine salts with org acids - using silver oxides
US4100293A (en) 1974-04-15 1978-07-11 The Johns Hopkins University Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids
US3950529A (en) 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
US4228099A (en) 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4320146A (en) 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4352814A (en) 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US4857555A (en) 1985-09-12 1989-08-15 Brigham & Women's Hospital Method of treating catabolic dysfunction
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US5139981A (en) 1987-06-24 1992-08-18 Union Carbide Chemicals & Plastics Technology Corporation Process for preparing silver(I)-exchanged resins
JP2522034B2 (ja) 1988-12-27 1996-08-07 味の素株式会社 α−ケト酸・アミノ酸塩化合物及びその製造方法
DE4020980C1 (zh) 1990-07-02 1991-09-26 Degussa Ag, 6000 Frankfurt, De
US5591613A (en) 1990-07-02 1997-01-07 Degussa Aktiengesellschaft Method for the preparation of D-arginine and L-ornithine
JP3127484B2 (ja) 1991-02-28 2001-01-22 味の素株式会社 肝炎治療薬
US5767086A (en) 1992-04-03 1998-06-16 Terrapin Technologies, Inc. Bone marrow stimulation by certain glutathione analogs
US5571783A (en) 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
JP3273578B2 (ja) 1993-09-21 2002-04-08 第一化学薬品株式会社 オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法
US6083953A (en) 1994-07-28 2000-07-04 Syntex (U.S.A.) Inc. 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative
IL139728A (en) 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
CN1175887A (zh) * 1995-02-23 1998-03-11 诺瓦蒂斯营养有限公司 氨基酸组合物及其在临床营养中的应用
WO1997030167A1 (en) 1996-02-13 1997-08-21 The Trustees Of The University Of Pennsylvania Method of treating liver disorders
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6258849B1 (en) 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
WO2000071151A1 (fr) 1999-05-21 2000-11-30 Takeda Chemical Industries, Ltd. Regulateurs des fonctions hepatiques
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
JP3211824B1 (ja) 2000-10-26 2001-09-25 味の素株式会社 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
CN1304723A (zh) 2001-01-16 2001-07-25 中山大学 含二氢呋喃环结构的丹参酮类化合物用于治疗肝性脑病的药物
JPWO2002074302A1 (ja) 2001-03-15 2005-07-14 独立行政法人理化学研究所 肝機能障害改善用アミノ酸組成物
US6503530B1 (en) 2001-11-01 2003-01-07 Chunghee Kimberly Kang Method of preventing development of severe metabolic derangement in inborn errors of metabolism
US20030105104A1 (en) 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20030195255A1 (en) * 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
CN1383815A (zh) 2002-05-08 2002-12-11 刘万忠 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法
US20040152784A1 (en) 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
JPWO2004019928A1 (ja) 2002-08-30 2005-12-15 味の素株式会社 肝疾患治療剤
US20050059150A1 (en) 2003-09-17 2005-03-17 Becton, Dickinson And Company Environments that maintain function of primary liver cells
MXPA03009902A (es) 2003-10-29 2005-05-03 Manuel Francisco Lara Och Jose Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio.
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2005108339A2 (en) 2004-05-06 2005-11-17 Osteologix A/S High yield and rapid syntheses methods for producing metallo-organic salts
WO2006059237A1 (en) 2004-08-30 2006-06-08 Lunamed, Inc. 4-phenylbutyric acid controlled-release formulations for therapeutic use
GB0426141D0 (en) * 2004-11-26 2004-12-29 Ucl Biomedica Plc Treatment
EA011716B1 (ru) * 2004-11-26 2009-04-28 Ю Си Эл БИЗНЕС Пи Эл Си Композиция, содержащая орнитин и фенилацетат или фенилбутират, для лечения печеночной энцефалопатии
WO2007077995A1 (ja) 2006-01-05 2007-07-12 Kyowa Hakko Kogyo Co., Ltd. 筋肉増量剤
DE102007009243A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
CA2727088A1 (en) 2008-06-04 2009-12-10 Phenolics, Llc Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same
SG174982A1 (en) 2009-04-03 2011-11-28 Ocera Therapeutics Inc L-ornithine phenyl acetate and methods of making thereof
AU2015221466B2 (en) 2009-04-03 2017-02-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
CA2763894A1 (en) 2009-06-02 2011-01-13 Salix Pharmaceuticals, Ltd. Use of rifaximin to maintain remission of hepatic encephalopathy
SG176675A1 (en) 2009-06-08 2012-01-30 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
AU2014250643B2 (en) 2009-06-08 2016-07-14 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
JP2011236160A (ja) 2010-05-11 2011-11-24 Shinshu Univ 非アルコール性肝疾患治療薬
CA2813563C (en) 2010-10-06 2019-02-26 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate
US9289406B2 (en) 2012-11-21 2016-03-22 Horizon Therapeutics, Inc. Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
CN103705490B (zh) 2013-10-31 2016-08-17 蚌埠丰原医药科技发展有限公司 一种门冬氨酸鸟氨酸的缓释制剂及其制备工艺
EA201790913A1 (ru) 2014-11-24 2017-11-30 Юсл Бизнес Плс Лечение заболеваний, связанных с активацией звездчатых клеток печени, с применением видов терапии, снижающих уровень аммиака
RU2755904C2 (ru) 2015-04-20 2021-09-22 Осера Терапьютикс, Инк. Составы l-орнитин фенилацетата
JP6990170B2 (ja) 2015-08-18 2022-01-12 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防
WO2017053613A1 (en) 2015-09-25 2017-03-30 Ocera Therapeutics, Inc. Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate

Also Published As

Publication number Publication date
JP6527497B2 (ja) 2019-06-05
CA2997484C (en) 2020-05-12
US20180161293A1 (en) 2018-06-14
JP2012529523A (ja) 2012-11-22
ZA201108988B (en) 2015-04-29
CN104434894A (zh) 2015-03-25
ES2728948T3 (es) 2019-10-29
BRPI1012956A8 (pt) 2021-11-03
JP5749255B2 (ja) 2015-07-15
CA2997484A1 (en) 2010-12-16
DK2799067T3 (da) 2019-06-03
AU2010258888A1 (en) 2012-02-02
EP2440200A2 (en) 2012-04-18
JP6250588B2 (ja) 2017-12-20
KR20120047891A (ko) 2012-05-14
IL216811A (en) 2016-11-30
NZ615091A (en) 2015-03-27
IL248696A0 (en) 2016-12-29
JP2017066153A (ja) 2017-04-06
CN102625699A (zh) 2012-08-01
AU2010258888B2 (en) 2014-08-07
MX2011013129A (es) 2012-03-14
EP2440200B8 (en) 2014-10-15
EP2440200A4 (en) 2012-11-28
IL248696B (en) 2020-05-31
US20120157526A1 (en) 2012-06-21
CA2764587A1 (en) 2010-12-16
EP2440200B1 (en) 2014-08-27
EA201691430A1 (ru) 2017-02-28
ES2517340T3 (es) 2014-11-03
PL2440200T3 (pl) 2015-08-31
JP2015163635A (ja) 2015-09-10
KR101715008B1 (ko) 2017-03-22
DK2440200T3 (en) 2014-12-08
EP2799067A1 (en) 2014-11-05
HK1203419A1 (zh) 2015-10-30
US11266620B2 (en) 2022-03-08
IL216811A0 (en) 2012-02-29
WO2010144498A9 (en) 2011-04-28
CN102625699B (zh) 2014-08-20
CA2764587C (en) 2018-04-24
EA201171396A1 (ru) 2012-10-30
EP3517110A1 (en) 2019-07-31
NZ596916A (en) 2013-09-27
MX2020009703A (es) 2020-10-07
KR20170026672A (ko) 2017-03-08
EP2799067B1 (en) 2019-04-03
BRPI1012956A2 (pt) 2017-06-06
SG176675A1 (en) 2012-01-30
WO2010144498A2 (en) 2010-12-16
EA025735B1 (ru) 2017-01-30

Similar Documents

Publication Publication Date Title
IL248696A0 (en) Treatment of portal hypertension and restoration of liver function by using l-orthenine phenylacetate
HK1220970A1 (zh) 偶聯物及其使用方法
EP2424857A4 (en) DOUBLE ACTION INHIBITORS AND METHODS OF USE
EP2255263A4 (en) REACHEMINER WITH TWO REFERENCE CLOCKS AND ITS ACTUATION METHOD
PL2288376T3 (pl) Sposoby generowania i wykorzystywania prokolagenu
PT2456304E (pt) Métodos de modulação de ácidos de cadeia ramificada e utilização dos mesmos
EP2370815A4 (en) ANTI-INFLAMMATORY COMPOSITIONS AND RELATED METHODS
EP2384518A4 (en) STRUCTURES AND METHOD FOR FIELD EFFECT DIODES WITH SELF-BOOTSTRAPPING
IL218815A0 (en) Methods and procucts using grass of the genus triodia
HK1173339A1 (zh) 螺內酰胺衍生物及其用途
IL207827A0 (en) Apoaequorin-containing compositions and methods of using same
HK1182311A1 (en) Nutritive compositions and methods of using same
GB0917927D0 (en) Ido inhibitors and therapeutic uses thereof
EP2385840A4 (en) MATERIALS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
GB0917926D0 (en) Ido inhibitors and therapeutic uses thereof
EP2365822A4 (en) SERPENT V FACTOR AND METHODS OF USE AS PROCOAGULANT
IL200674A0 (en) Solar arrangement and method of use
GB0921929D0 (en) Compositions and methods for the treatment of influenza
IL206538A0 (en) Guitar and method of using same
AU2010903136A0 (en) Herbal composition and a method of treatment using the composition
TWM385437U (en) Socket tool capable of fastening and loosening
AU2009905861A0 (en) Fastener and Method of Applying Fastener
IL208780A0 (en) Methods of generating and using procollagen